Instil Bio (TIL) Stock
Early-stage developer of immune-based therapies for solid tumours. Here's the price, business snapshot, and what's worth knowing about Instil Bio in November 2026.
Instil Bio, Inc. (TIL) is a clinical-stage biotechnology company developing tumour-infiltrating lymphocyte (TIL) and engineered T‑cell therapies intended to treat solid tumours. The company's value proposition centres on early clinical programmes and technology that aim to harness patients' immune systems to attack cancer. With a market capitalisation around $128M, Instil is an early-stage, research-driven business: revenues are limited and valuation is sensitive to trial readouts, regulatory news and funding activity. Investors should be aware that potential upside from positive clinical data or strategic partnerships is balanced by significant risks — clinical failures, manufacturing complexity, regulatory delays and possible dilution from capital raises. This summary is for general educational purposes only and not personal investment advice. It’s important to consider your own risk tolerance, diversify holdings and seek independent financial advice before making investment decisions.
Instil Bio (TIL) Stock Forecast
Analyst price target, next 12 months
$27.25
+378.9% vs today's $5.69
Price range over the last 12 months
Close to its 12-month low
Analysts covering Instil Bio have a consensus 12-month target of $27.25, above the current price of $5.69.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Instil Bio's stock with a target price of $27.25, indicating possible future gains.
Financial Health
Instil Bio is showing strong financial performance with good cash flow and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical readouts matter
Early-stage trial results largely determine valuation; strong data can create upside, but outcomes are binary and unpredictable.
Manufacturing and scale challenges
Cell therapies require specialised manufacturing and scale-up, which can delay timelines and raise costs; these operational issues are material risks.
Partnerships can de‑risk
Collaborations or licensing deals may provide funding and validation, though they are not guaranteed and depend on clinical and commercial progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
